Mode
Text Size
Log in / Sign up

Coronary Artery Disease

Part of Myocardial ischemia

Subtypes of Coronary Artery Disease

Percutaneous Coronary Intervention 7 Calcified Coronary Lesions 2 Coronary bifurcation lesions 2 Spontaneous coronary artery dissection 2 Angina with No Obstructive Coronary Artery Disease 1 Angina with nonobstructive coronary arteries 1 Bifurcation percutaneous coronary intervention 1 Complex Coronary Artery Disease 1 Complex coronary artery lesions 1 Complex Coronary Lesions 1 Complex percutaneous coronary intervention 1 Coronary artery aneurysm 1 Coronary Artery Bypass Graft (CABG) 1 Coronary artery calcification 1 Coronary artery lesion 1 Coronary atherosclerotic heart disease 1 Coronary bifurcation stenosis 1 Coronary slow flow phenomenon 1 Established coronary artery disease 1 Extensive coronary artery disease 1 Giant coronary artery aneurysms 1 High-risk coronary revascularisation 1 Ischemia with No Obstructive Coronary Artery Disease 1 Left Main Coronary Artery Stenosis 1 Myocardial infarction with non-obstructive coronary arteries (MINOCA) 1 Non-ischemic heart diseases 1 Non-obstructive coronary artery disease 1 Non-ST elevation acute coronary syndrome 1 Noncomplex coronary bifurcation lesions 1 Obstructive Coronary Artery Disease 1 Post-percutaneous coronary intervention 1 Unprotected left main coronary artery disease 1 Vasospastic coronary heart disease 1 Complex coronary bifurcation lesions 0 Coronary artery fistula 0 De novo non-complex coronary artery disease 0 High-risk percutaneous coronary intervention 0 Intermediate coronary artery stenoses 0

132 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Coronary Artery Disease

476 trials tracked for Coronary Artery Disease: 164 in phase 3 or 4 and 55 with published results. The most-cited published study has 2930 citations.

476Trials tracked
164Phase 3 & 4
0Recruiting
55With published results
Phase distribution
Phase 4 88 Phase 3 76 Phase 2 62 Phase 1 14 Other / NA 236
  1. Phase 3 Colchicine Cardiovascular Outcomes Trial (COLCOT) Completed · 2,930 cited
  2. Phase 3 Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) Completed · 2,327 cited
  3. Phase 3 Prevention of Serious Adverse Events Following Angiography Completed · 501 cited
  4. Phase 3 The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial Completed · 456 cited
  5. Phase 3 Imaging of Coronary Plaques in Participants Treated With Evolocumab Completed · 426 cited
  6. Phase 4 Tailored Antiplatelet Therapy Following PCI Completed · 402 cited
Show 44 more trials
  1. Phase 3 A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes Completed · 356 cited
  2. Phase 4 Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy Completed · 278 cited
  3. Phase 3 A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) Completed · 243 cited
  4. Phase 4 The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial Completed · 221 cited
  5. Phase 4 Anti-inflammatory Effects of Colchicine in PCI Completed · 181 cited
  6. Phase 4 Colchicine in Percutaneous Coronary Intervention Completed · 181 cited
  7. Phase 3 Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD Completed · 161 cited
  8. Phase 3 A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD. Completed · 141 cited
  9. Phase 3 Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial Completed · 136 cited
  10. Phase 4 Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication Completed · 129 cited
  11. Phase 4 Pharmacological Effects of Crushing Prasugrel in STEMI Patients Completed · 123 cited
  12. Phase 3 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome Completed · 118 cited
  13. Phase 3 Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI) Completed · 116 cited
  14. Phase 3 An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD) Completed · 99 cited
  15. Phase 3 A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure Completed · 97 cited
  16. Phase 4 Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Completed · 86 cited
  17. Phase 4 The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY) Completed · 67 cited
  18. Phase 4 EVOLVE Short DAPT Study Completed · 66 cited
  19. Phase 4 ISCHEMIA-Chronic Kidney Disease Trial Completed · 63 cited
  20. Phase 3 Targeting Inflammation Using Salsalate in CardioVascular Disease Completed · 61 cited
  21. Phase 4 Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease Completed · 56 cited
  22. Phase 3 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation Completed · 50 cited
  23. Phase 3 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD Completed · 49 cited
  24. Phase 3 Glutamate for Metabolic Intervention in Coronary Surgery Completed · 46 cited
  25. Phase 4 Reversing Ticagrelor's Effects With Fresh Platelets Completed · 43 cited
  26. Phase 3 Metformin to Reduce Heart Failure After Myocardial Infarction Completed · 42 cited
  27. Phase 3 Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS Completed · 39 cited
  28. Phase 4 Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine Completed · 36 cited
  29. Phase 4 PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment Completed · 35 cited
  30. Phase 4 A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function: Completed · 27 cited
  31. Phase 4 Ranitidin Versus Omeprazole in Patients Taking Clopidogrel Completed · 26 cited
  32. Phase 4 Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies Completed · 23 cited
  33. Phase 4 Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI Completed · 20 cited
  34. Phase 4 AngioSeal Versus Radial Approach in Acute Coronary Syndrome Completed · 18 cited
  35. Phase 4 PROMUS Element Plus US Post-Approval Study Completed · 16 cited
  36. Phase 4 Effects of Linagliptin on Endothelial Function Completed · 16 cited
  37. Phase 4 Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients Completed · 15 cited
  38. Phase 4 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina Completed · 15 cited
  39. Phase 4 Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI Completed · 14 cited
  40. Phase 4 A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease Completed · 11 cited
  41. Phase 4 Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Completed · 10 cited
  42. Phase 4 A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart Completed · 9 cited
  43. Phase 3 Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia Completed · 9 cited
  44. Phase 4 Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease Completed · 8 cited

Showing the 50 most-cited and recently-updated of 476 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

Coronary Artery Disease: current evidence & treatments

Pre-existing coronary artery disease (CAD) significantly worsens outcomes in kidney transplant recipients, increasing all-cause mortality (HR 1.68) and post-transplant cardiovascular events 1. In the general CAD population, higher pan-immune-inflammation value (PIV) is associated with worse outcomes after PCI for acute coronary syndrome, including MACE (aHR 1.65) and all-cause mortality (HR 3.51) 3. Additionally, systemic lupus erythematosus elevates CAD risk (RR 2.355) 18, and breast arterial calcification on mammography predicts higher cardiovascular event risk in women (HR 1.82) 7. Active cancer in ACS patients is linked to higher mortality, though PCI may mitigate risk 23.

Pharmacological interventions show benefit: colchicine reduces MACE and myocardial infarction in CAD without increasing serious adverse events 4. Inclisiran plus usual care improves LDL-C goal attainment after ACS (74.6% vs 26.6% at Day 90) 16. Ticagrelor is approved for multiple indications, including ACS and high-risk CAD 24. Exercise, particularly high-intensity interval aerobic exercise, improves brachial FMD in CAD and heart failure 2. Regarding revascularization strategies, polymer-free and biodegradable-polymer DES show comparable outcomes in PCI 5, while drug-coated balloons (DCB) are associated with higher target lesion revascularization compared to DES (OR 2.22) 19. In bifurcation lesions, paclitaxel drug-coated balloons reduce MACE versus limus-eluting stents 8, and the jailed balloon technique may reduce side-branch occlusion compared to jailed wire 22. OCT guidance in left main bifurcation disease showed non-significant MACE reduction versus angiography 21.

Residual angina occurs in 42.2% of patients after anatomic complete revascularization for chronic coronary disease 17. Serum resistin levels rise progressively with worsening CAD severity 9. Pre-infection COVID-19 vaccination is linked to lower cardiovascular and cerebrovascular event risks in SARS-CoV-2 infected individuals 11. In severe aortic stenosis with CAD, PCI before TAVR reduces revascularization but increases bleeding risk 13. Sudden cardiac death risk in marathon runners is higher in men, older runners, and full-marathon participants, with CAD as the predominant cause in middle-aged and older runners 10. Strategic collaborations are needed to expand interventional cardiology access in sub-Saharan Africa 20.

Key drugs in the evidence

sirolimus 4 statin 3 aspirin 3 paclitaxel 3 ticagrelor 3 colchicine 2 heparin 2 ramipril 2 clopidogrel 2 nicotine 1

Latest findings

AI-generated synthesis of 20 cited studies, updated Jun 12, 2026. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Myocardial ischemia

Related studies from across the Myocardial ischemia family.

IVUS-guided PCI shows no significant difference over angiography-guided PCI for primary outcomes
Cardiology RCT
IVUS-guided PCI shows no significant difference over angiography-guided PCI for primary outcomes Trial shows ultrasound imaging adds no benefit for heart surgery
This randomized controlled trial of 806 patients with unprotected left main coronary artery disease found that IVUS-guided PCI did not signi…
A large trial found that using ultrasound guidance during certain heart procedures did not improve safety or outcomes compared to standard m…
Staged revascularization shows no significant difference versus immediate revascularization for major adverse cardiovascular events in STEMI and MVD patients
Cardiology Meta-analysis
Staged revascularization shows no significant difference versus immediate revascularization for major adverse cardiovascular events in STEMI and MVD patients Timing of heart surgery does not change survival for a specific heart attack group
This meta-analysis reviewed 5077 patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease comparing …
A large review found that waiting for staged heart surgery did not improve survival or reduce heart attacks compared to immediate surgery fo…
OCT guidance showed non-significant MACE reduction in true unprotected left main bifurcation disease compared to angiography
Cardiology RCT
OCT guidance showed non-significant MACE reduction in true unprotected left main bifurcation disease compared to angiography Doctors used special imaging tools to help place stents in heart arteries safely
This randomized controlled trial enrolled 227 patients with true unprotected left main bifurcation lesions. Optical coherence tomography (OC…
A study tested using optical coherence tomography to guide stent placement in complex heart artery cases. While the imaging was mostly succe…
Five-year economic and quality of life outcomes favor PCI with zotarolimus stents over CABG in 3-vessel CAD
Cardiology RCT
Five-year economic and quality of life outcomes favor PCI with zotarolimus stents over CABG in 3-vessel CAD Five-year follow-up reveals lower costs and better employment for PCI over surgery in complex heart disease
This randomized trial compared fractional flow reserve-guided PCI using zotarolimus drug-eluting stents with coronary artery bypass grafting…
Patients with complex heart disease treated with stents had lower costs and better quality of life than those who had surgery after five yea…
Retrospective cohort finds inverse triglyceride relationship with mortality in left main coronary artery disease
Cardiology Cohort
Retrospective cohort finds inverse triglyceride relationship with mortality in left main coronary artery disease Low Fat, High Risk: Why Less Triglyceride Means Longer Life
This retrospective cohort study evaluated 2,778 patients with left main coronary artery disease undergoing percutaneous coronary interventio…
Imagine your heart is a busy highway. For years, doctors thought high cholesterol was the only traffic jam causing crashes.
Narrative review outlines practical framework for combined lipid and anti-inflammatory therapy in coronary atherosclerosis
Cardiology Sys. Review
Narrative review outlines practical framework for combined lipid and anti-inflammatory therapy in coronary atherosclerosis Your Heart Has a Hidden Fire
This narrative review examines the role of colchicine and IL-1β inhibitors in patients with coronary atherosclerosis.
Doctors now know you must fight two enemies at once: the bad fats in your blood and the hidden inflammation that makes them dangerous.
Narrative mini-review discusses mechanisms driving coronary atherosclerosis in patients with systemic lupus erythematosus
Allergy & Immunology Sys. Review
Narrative mini-review discusses mechanisms driving coronary atherosclerosis in patients with systemic lupus erythematosus Why Lupus Can Speed Up Heart Disease, Even in Young People
This narrative mini-review synthesizes mechanistic insights regarding the link between systemic lupus erythematosus and coronary atheroscler…
Understanding how lupus harms blood vessels could help prevent heart attacks in people who don’t look high-risk.
FFR-guided complete revascularization reduces unplanned revascularization in MI patients with multivessel CAD
Cardiology Meta-analysis
FFR-guided complete revascularization reduces unplanned revascularization in MI patients with multivessel CAD Complete Heart Repair May Stop Future Emergencies
A meta-analysis of 3,054 patients with myocardial infarction and multivessel coronary artery disease found that FFR-guided complete revascul…
Fixing all blocked heart arteries during surgery may stop future emergencies and unplanned procedures for patients with heart attacks.
Ticagrelor Not Noninferior to Prasugrel in Diabetes Patients With Multivessel CAD After PCI
Cardiology RCT
Ticagrelor Not Noninferior to Prasugrel in Diabetes Patients With Multivessel CAD After PCI New study shows ticagrelor did not beat prasugrel for heart attack prevention in diabetics
This randomized clinical trial of 1,800 patients with diabetes and multivessel coronary artery disease undergoing PCI compared ticagrelor pl…
For diabetics with heart stents, a new study found ticagrelor offered no clear advantage over prasugrel in preventing death, heart attacks, …
iFR-guided CABG improves mid-term graft patency versus angiography alone in multivessel disease
Cardiology RCT
iFR-guided CABG improves mid-term graft patency versus angiography alone in multivessel disease Can a simple test during heart surgery help grafts stay open longer?
A single-blinded RCT in patients with multivessel disease and intermediate stenoses found iFR-guided CABG significantly improved LIMA-to-LAD…
A simple pressure test during heart surgery keeps new blood vessel grafts open longer, with 80.5% staying clear versus 56.8% with standard i…
Colchicine reduces total plaque burden but not low attenuation plaque in stable CAD patients
Cardiology RCT
Colchicine reduces total plaque burden but not low attenuation plaque in stable CAD patients Can a cheap anti-inflammatory drug slow heart disease? It might help reduce plaque buildup
In the EKSTROM RCT (n=84), low-dose colchicine (0.5 mg/day) did not significantly reduce low attenuation plaque volume (median change 0.1 vs…
A cheap anti-inflammatory drug called colchicine may help slow total plaque buildup in arteries for people already managing stable heart dis…

Questions about Coronary Artery Disease

Is having lower blood pressure at the start of treatment linked to higher risk in stable CAD?

Yes, a post-hoc analysis of the AFIRE trial found that in patients with atrial fibrillation and stable CAD, lower baseline systolic blood pressure (≤126 mmHg) was linked to higher cardiovascular risk compared to higher SBP.

Full answer →
Can an AI model help doctors decide on my treatment plan for Percutaneous Coronary Intervention?

AI models are not yet proven to help doctors decide on PCI treatment plans; current research focuses on imaging and risk scores, not AI decision support.

Full answer →
Does having metabolic syndrome increase my risk of restenosis after Percutaneous Coronary Intervention?

Current evidence does not show a clear link between metabolic syndrome and higher restenosis risk after PCI, though related factors like insulin resistance may play a role.

Full answer →
Is proton pump inhibitor use increasing for Chinese patients with acute coronary syndrome?

Yes, PPI use is increasing among Chinese ACS patients, rising from 21.3% (2010-2012) to 63.5% (2016-2018) in one study, with over 60% prescribed PPIs in a 2017-2018 registry.

Full answer →
What drug-drug interactions should I watch for while hospitalized with acute coronary syndrome?

While hospitalized for acute coronary syndrome, watch for interactions between blood thinners (aspirin, ticagrelor, heparin) and other drugs like ramipril, PPIs, and smoking cessation aids; your care team monitors these closely.

Full answer →
Do SGLT-2 inhibitors help reduce heart failure hospitalization for acute coronary syndrome?

Yes, SGLT-2 inhibitors reduce the risk of first heart failure hospitalization in patients with acute coronary syndrome, according to a 2024 meta-analysis.

Full answer →
Does using imaging guidance during stenting lower heart attack risk for older patients with coronary artery disease?

Yes, imaging guidance (IVUS or OCT) during stenting lowers heart attack and MACE risk in older patients, according to a 2024 meta-analysis of 9 RCTs.

Full answer →
Can a CT scan accurately measure my coronary artery disease blockages compared to invasive tests?

CT scans (CCTA) can detect blockages but tend to underestimate their severity compared to invasive angiography, so they are not a perfect replacement.

Full answer →
See all 11 questions about Coronary Artery Disease →

All Coronary Artery Disease Articles